SOURCE: Vivakor, Inc.

December 21, 2009 08:00 ET

Vivakor's Management Sees New Opportunities in Stem Cell Research

CORALVILLE, IA--(Marketwire - December 21, 2009) - Vivakor, Inc. (OTCBB: VIVK) -- With the recent authorization of 13 new stem lines by the National Institutes of Health and another 96 new lines awaiting federal approval, combined with the Obama administration's focus on funding research on these newly released stem cell lines (31 grants worth approximately $21 million have already been approved by the NIH), Vivakor and its biological handling division have a unique opportunity to seize on this suddenly red hot market. Vivakor's Executive Chairman, Matt Nicosia, was quoted: "Vivakor's VivaThermic division and its cryovials present a dramatic new tool for researchers in this incredibly important and commercially exploding field. We plan on playing a large role by establishing our cryovials as the new 'gold standard' for use in many of the research areas which utilize stem cells and cryopreservation of the cells."

Vivakor's CEO and Chief Scientific Officer, Dr. Tannin Fuja, recently noted in a previous announcement that "Testing results show that the VivaThermic Ultra vials give a 300% better temperature control than standard cryovials or microcentrifuge tubes. For example, if a user wants to freeze a sample slowly, using precise temperature control, the VivaThermic vials give superior precision; or, if a user wants to thaw a sample quickly, the VivaThermic vials will thaw the sample 3 times faster than market leading vials." With results like these it is clear that the company's optimism for the opportunity in the new stem cell research field is well placed.

About Vivakor, Inc.

Vivakor is a biomedical/biotechnology company with transdisciplinary research that develops and acquires products in the fields of molecular medicine, electro-optics, biological handling and natural and formulary compounds, that extend or improve life. More information can be found about Vivakor at


This press release may contain forward-looking statements, including, but not limited to, statements regarding Vivakor's products, markets and business strategies. Forward-looking statements may be identified by the use of the words "anticipates," "expects," "intends," "plans," "should," "could," "would," "may," "will," "believes," "estimates," "potential," or "continue" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties discussed in Vivakor's filings with the Securities and Exchange Commission, which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. Vivakor undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this press release or to reflect actual outcomes.